{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:35:48Z","timestamp":1762101348468,"version":"build-2065373602"},"reference-count":124,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.rdc.2012.08.004","type":"journal-article","created":{"date-parts":[[2012,9,15]],"date-time":"2012-09-15T09:15:20Z","timestamp":1347700520000},"page":"613-633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Therapeutic Controversies"],"prefix":"10.1016","volume":"38","author":[{"given":"I.H.","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.P.","family":"Maksymowych","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.rdc.2012.08.004_bib1","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/ard.2011.151563","article-title":"2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis","volume":"70","author":"van der Heijde","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2012.08.004_bib2","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.rdc.2012.08.004_bib3","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.rdc.2012.08.004_bib4","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.rdc.2012.08.004_bib5","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2012.08.004_bib6","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3346\/jkms.2002.17.5.669","article-title":"Higher prevalence of peripheral arthritis among ankylosing spondylitis patients","volume":"17","author":"Lee","year":"2002","journal-title":"J\u00a0Korean Med Sci"},{"issue":"12","key":"10.1016\/j.rdc.2012.08.004_bib7","doi-asserted-by":"crossref","first-page":"896","DOI":"10.7326\/0003-4819-136-12-200206180-00011","article-title":"Update on spondyloarthropathies","volume":"136","author":"Khan","year":"2002","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.rdc.2012.08.004_bib8","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/rheumatology\/kep146","article-title":"Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice","volume":"48","author":"Elewaut","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.rdc.2012.08.004_bib9","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1136\/ard.2006.064543","article-title":"The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice","volume":"66","author":"Vander Cruyssen","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.rdc.2012.08.004_bib10","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1002\/art.20754","article-title":"Effect of etanercept on iritis in patients with ankylosing spondylitis","volume":"50","author":"Rosenbaum","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2012.08.004_bib11","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1529-0131(200106)45:3<252::AID-ART257>3.0.CO;2-5","article-title":"Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease","volume":"45","author":"Smith","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.rdc.2012.08.004_bib12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/ncprheum0225","article-title":"Severe uveitis in an HLA-B27-positive patient with ankylosing spondylitis","volume":"2","author":"Monnet","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2012.08.004_bib13","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/ard.2007.077370","article-title":"Uveitis and tumour necrosis factor blockade in ankylosing spondylitis","volume":"67","author":"Coates","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2012.08.004_bib14","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.semarthrit.2011.05.005","article-title":"New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases","volume":"41","author":"Wendling","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.rdc.2012.08.004_bib15","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1136\/ard.2006.052092","article-title":"Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study","volume":"65","author":"Guignard","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2012.08.004_bib16","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/rheumatology\/ken091","article-title":"Do TNF-blockers reduce or induce uveitis?","volume":"47","author":"Cobo-Ibanez","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.rdc.2012.08.004_bib17","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1002\/art.22918","article-title":"Do tumor necrosis factor inhibitors cause uveitis? A registry-based study","volume":"56","author":"Lim","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2012.08.004_bib18","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard.2008.092585","article-title":"Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2012.08.004_bib19","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2012.08.004_bib20","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/ard.2008.103192","article-title":"Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials","volume":"69","author":"Sieper","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"9244","key":"10.1016\/j.rdc.2012.08.004_bib21","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/S0140-6736(00)03239-6","article-title":"Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms","volume":"356","author":"Van den Bosch","year":"2000","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.rdc.2012.08.004_bib22","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1136\/ard.2003.012450","article-title":"Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations","volume":"63","author":"Generini","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2012.08.004_bib23","unstructured":"Humira\u00ae (Adalimumab) Summary of Product Characteristics (SPC). February 2008."},{"issue":"1","key":"10.1016\/j.rdc.2012.08.004_bib24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/ard.62.1.74","article-title":"Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis","volume":"62","author":"Marzo-Ortega","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2012.08.004_bib25","unstructured":"Enbrel\u00ae (Etanercept) Summary of Product Characteristics (SPC). July 2008."},{"issue":"5","key":"10.1016\/j.rdc.2012.08.004_bib26","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.rdc.2012.08.004_bib27","first-page":"532","article-title":"New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept","volume":"35","author":"Song","year":"2008","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2012.08.004_bib28","unstructured":"Remicade\u00ae (Infliximab) Summary of Product Characteristics (SPC). August 2008."},{"issue":"4","key":"10.1016\/j.rdc.2012.08.004_bib29","first-page":"951","article-title":"Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis","volume":"26","author":"van der Heijde","year":"1999","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2012.08.004_bib30","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1136\/ard.2009.108217","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.rdc.2012.08.004_bib31","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/art.1780341003","article-title":"The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy","volume":"34","author":"Dougados","year":"1991","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2012.08.004_bib32","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/art.24483","article-title":"The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort","volume":"60","author":"Rudwaleit","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2012.08.004_bib33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/ard.46.3.197","article-title":"Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis","volume":"46","author":"Mander","year":"1987","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2012.08.004_bib34","first-page":"993","article-title":"Stoke ankylosing spondylitis spine score","volume":"26","author":"Dawes","year":"1999","journal-title":"J\u00a0Rheumatol"},{"issue":"18","key":"10.1016\/j.rdc.2012.08.004_bib35","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha","volume":"346","author":"Gorman","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.rdc.2012.08.004_bib36","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/ard.62.2.127","article-title":"Assessment of enthesitis in ankylosing spondylitis","volume":"62","author":"Heuft-Dorenbosch","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2012.08.004_bib37","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/art.11017","article-title":"Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis","volume":"48","author":"Brandt","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2012.08.004_bib38","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/ard.2007.084244","article-title":"Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index","volume":"68","author":"Maksymowych","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2012.08.004_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2012-eular.2240","article-title":"Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised, placebo-controlled trial (ABILITY-1)","author":"Sieper","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2012.08.004_bib40","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1136\/ard.2009.121533","article-title":"A\u00a0randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial","volume":"69","author":"Dougados","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2012.08.004_bib41","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/ard.2010.139667","article-title":"Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial","volume":"70","author":"Song","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2012.08.004_bib42","doi-asserted-by":"crossref","first-page":"R3","DOI":"10.1186\/ar3551","article-title":"Anterior chest wall inflammation by whole-body magnetic resonance imaging in patients with spondyloarthritis: lack of association between clinical and imaging findings in a cross-sectional study","volume":"14","author":"Weber","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.rdc.2012.08.004_bib43","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s10067-011-1722-5","article-title":"Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease","volume":"30","author":"Navarro-Compan","year":"2011","journal-title":"Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.rdc.2012.08.004_bib44","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s10067-010-1542-z","article-title":"Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysis","volume":"29","author":"Lee","year":"2010","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2012.08.004_bib45","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10067-007-0674-2","article-title":"Etanercept 25 mg\/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients","volume":"27","author":"Lee","year":"2008","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2012.08.004_bib46","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.3899\/jrheum.111337","article-title":"Dosage adjustment of anti-tumor necrosis factor-alpha inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice","volume":"39","author":"Paccou","year":"2012","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2012.08.004_bib47","first-page":"510","article-title":"Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis","volume":"34","author":"Baraliakos","year":"2007","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2012.08.004_bib48","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/rheumatology\/keh475","article-title":"Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis","volume":"44","author":"Brandt","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.rdc.2012.08.004_bib49","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/art.23606","article-title":"Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two","volume":"58","author":"Haibel","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"Suppl 10","key":"10.1016\/j.rdc.2012.08.004_bib50","first-page":"S503","article-title":"Long term results of a remission induction approach to early axial spondyloarthritis: still looking for the window of opportunity","volume":"63","author":"Ash","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.rdc.2012.08.004_bib51","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1136\/annrheumdis-2011-201010","article-title":"Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial","volume":"71","author":"Song","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2012.08.004_bib52","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","article-title":"Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis","volume":"44","author":"Anderson","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2012.08.004_bib53","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.rdc.2012.08.004_bib54","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/rheumatology\/ker083","article-title":"High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study)","volume":"50","author":"Navarro-Sarabia","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"14","key":"10.1016\/j.rdc.2012.08.004_bib55","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.rdc.2012.08.004_bib56","first-page":"661","article-title":"The formation of autoantibodies and antibodies to TNF-alpha blocking agents in relation to clinical response in patients with ankylosing spondylitis","volume":"28","author":"Arends","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2012.08.004_bib57","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/ard.2006.057745","article-title":"Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation","volume":"66","author":"de Vries","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.rdc.2012.08.004_bib58","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1136\/ard.2009.109702","article-title":"Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation","volume":"68","author":"de Vries","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2012.08.004_bib59","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/ard.2008.089979","article-title":"Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis","volume":"68","author":"de Vries","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"2\u20133","key":"10.1016\/j.rdc.2012.08.004_bib60","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12016-009-8140-3","article-title":"Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases","volume":"38","author":"Emi Aikawa","year":"2010","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.rdc.2012.08.004_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2011-200828","article-title":"Influence of immunogenicity on the efficacy of long-term treatment of spondyloarthritis with infliximab","author":"Plasencia","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2012.08.004_bib62","doi-asserted-by":"crossref","first-page":"R105","DOI":"10.1186\/ar3386","article-title":"Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases","volume":"13","author":"Ducourau","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.rdc.2012.08.004_bib63","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/ard.2006.065615","article-title":"Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis","volume":"66","author":"Bartelds","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.rdc.2012.08.004_bib64","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"15","key":"10.1016\/j.rdc.2012.08.004_bib65","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.rdc.2012.08.004_bib66","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/rheumatology\/ken207","article-title":"Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation","volume":"47","author":"Li","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.rdc.2012.08.004_bib67","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/art.23167","article-title":"Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment","volume":"58","author":"Breban","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.rdc.2012.08.004_bib68","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/art.23333","article-title":"The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study","volume":"59","author":"Heiberg","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2012.08.004_bib69","doi-asserted-by":"crossref","first-page":"R82","DOI":"10.1186\/ar3350","article-title":"Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study","volume":"13","author":"Mulleman","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1016\/j.rdc.2012.08.004_bib70","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/ard.2004.032441","article-title":"Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept","volume":"64","author":"Rudwaleit","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.rdc.2012.08.004_bib71","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1002\/art.23044","article-title":"Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study","volume":"56","author":"Lambert","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.rdc.2012.08.004_bib72","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.3899\/jrheum.091043","article-title":"Low-dose infliximab (3 mg\/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study","volume":"37","author":"Maksymowych","year":"2010","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2012.08.004_bib73","doi-asserted-by":"crossref","first-page":"R104","DOI":"10.1186\/ar2496","article-title":"The relationship between inflammation and new bone formation in patients with ankylosing spondylitis","volume":"10","author":"Baraliakos","year":"2008","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.rdc.2012.08.004_bib74","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1136\/annrheumdis-2011-200208","article-title":"MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis","volume":"71","author":"van der Heijde","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2012.08.004_bib75","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/art.24132","article-title":"Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation","volume":"60","author":"Maksymowych","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.rdc.2012.08.004_bib76","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1002\/art.30393","article-title":"Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis","volume":"63","author":"Chiowchanwisawakit","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.rdc.2012.08.004_bib77","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3899\/jrheum.100925","article-title":"Resolution of inflammation following treatment of ankylosing spondylitis is associated with new bone formation","volume":"38","author":"Pedersen","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2012.08.004_bib78","article-title":"Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification","author":"Maksymowych","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2012.08.004_bib79","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nrrheum.2009.258","article-title":"Disease modification in ankylosing spondylitis","volume":"6","author":"Maksymowych","year":"2010","journal-title":"Nat Rev Rheumatol"},{"issue":"Suppl 3","key":"10.1016\/j.rdc.2012.08.004_bib80","first-page":"262","article-title":"What is the association between inflammation and focal fat infiltration in AS and does treatment matter?","volume":"69","author":"Chiowchanwisawakit","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.rdc.2012.08.004_bib81","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1136\/ard.2010.147033","article-title":"Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48","volume":"70","author":"Song","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2012.08.004_bib82","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","article-title":"Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial","volume":"52","author":"Wanders","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2012.08.004_bib83","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2011-201252","article-title":"Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort","author":"Poddubnyy","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2012.08.004_bib84","article-title":"Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis","author":"Kroon","year":"2012","journal-title":"Annals Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2012.08.004_bib85","first-page":"1010","article-title":"Switching between tumour necrosis factor blockers in spondyloarthritis: a retrospective monocentre study of 222 patients","volume":"29","author":"Dadoun","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"10.1016\/j.rdc.2012.08.004_bib86","first-page":"2183","article-title":"Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data","volume":"32","author":"Delaunay","year":"2005","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2012.08.004_bib87","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/art.22236","article-title":"Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study","volume":"55","author":"Cantini","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2012.08.004_bib88","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/rheumatology\/ken094","article-title":"Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis","volume":"47","author":"Coates","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.rdc.2012.08.004_bib89","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/ard.2007.073569","article-title":"Switching tumour necrosis factor alpha\u00a0antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period","volume":"66","author":"Conti","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.rdc.2012.08.004_bib90","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/rheumatology\/ken334","article-title":"Switching anti-TNF therapy in ankylosing spondylitis","volume":"47","author":"Pradeep","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.rdc.2012.08.004_bib91","doi-asserted-by":"crossref","first-page":"R117","DOI":"10.1186\/ar3054","article-title":"Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy","volume":"12","author":"Rudwaleit","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.rdc.2012.08.004_bib92","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/ard.2010.131797","article-title":"Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register","volume":"70","author":"Lie","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2012.08.004_bib93","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 3","key":"10.1016\/j.rdc.2012.08.004_bib94","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/annrheumdis-2012-eular.1851","article-title":"Clinical response, drug survival and predictors thereof in 432 patients with ankylosing spondylitis switching anti tumor necrosis factor \u03b1 therapy: results form the Danish nationwide DANBIO registry","volume":"71","author":"Glintborg","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2012.08.004_bib95","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/BOR.0b013e328346f7fb","article-title":"New treatment targets in ankylosing spondylitis and other spondyloarthritides","volume":"23","author":"Song","year":"2011","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2012.08.004_bib96","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/ard.2003.016386","article-title":"Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis","volume":"63","author":"Rudwaleit","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2012.08.004_bib97","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3899\/jrheum.081048","article-title":"Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis","volume":"36","author":"Rudwaleit","year":"2009","journal-title":"J\u00a0Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2012.08.004_bib98","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/art.24408","article-title":"Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis","volume":"60","author":"Barkham","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2012.08.004_bib99","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E","article-title":"Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab","volume":"43","author":"Brandt","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.rdc.2012.08.004_bib100","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1093\/rheumatology\/keh713","article-title":"The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis","volume":"44","author":"Barkham","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.rdc.2012.08.004_bib101","first-page":"79","article-title":"Estimation of the Bath Ankylosing Spondylitis Disease Activity Index cutoff for perceived symptom relief in patients with spondyloarthropathies","volume":"33","author":"Cohen","year":"2006","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2012.08.004_bib102","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/art.22469","article-title":"Evaluation and validation of the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis","volume":"57","author":"Maksymowych","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"Suppl 3","key":"10.1016\/j.rdc.2012.08.004_bib103","first-page":"521","article-title":"How much inflammation do patients with axial spondyloarthritis have who report low levels of disease activity? A prospective cohort study","volume":"70","author":"Kiltz","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.rdc.2012.08.004_bib104","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/rheumatology\/41.11.1280","article-title":"Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study","volume":"41","author":"Breban","year":"2002","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 3","key":"10.1016\/j.rdc.2012.08.004_bib105","first-page":"631","article-title":"A\u00a0substantial proportioin of AS patients respond to TNF inhibitors despite not fulfilling the criteria for initiating anti-TNF therapy according to the ASAS\/EULAR recommendations","volume":"68","author":"Heiberg","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.rdc.2012.08.004_bib106","first-page":"2273","article-title":"The Canadian Rheumatology Association\/ Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis: a national multidisciplinary stakeholder project","volume":"34","author":"Maksymowych","year":"2007","journal-title":"J\u00a0Rheumatol"},{"issue":"10","key":"10.1016\/j.rdc.2012.08.004_bib107","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1002\/art.30505","article-title":"Biosimilars: the debate continues","volume":"63","author":"Colbert","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"Suppl3","key":"10.1016\/j.rdc.2012.08.004_bib108","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/annrheumdis-2012-eular.1850","article-title":"Randomized, double-blind, phase 1 study demonstrates equivalence in pharmacokinetics, safety, and efficacy of CT-P13 and infliximab in patients with ankylosing spondylitis","volume":"71","author":"Park","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.rdc.2012.08.004_bib109","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.2165\/11593730-000000000-00000","article-title":"Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations","volume":"71","author":"Dranitsaris","year":"2011","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.rdc.2012.08.004_bib110","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/annonc\/mdm345","article-title":"The challenge of biosimilars","volume":"19","author":"Mellstedt","year":"2008","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.rdc.2012.08.004_bib111","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1517\/14712591003796553","article-title":"Biosimilars: current status and future directions","volume":"10","author":"Roger","year":"2010","journal-title":"Expert Opin Biol Ther"},{"issue":"8","key":"10.1016\/j.rdc.2012.08.004_bib112","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.3899\/jrheum.100995","article-title":"Does anti-tumor necrosis factor-alpha therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data","volume":"38","author":"Keystone","year":"2011","journal-title":"J\u00a0Rheumatol"},{"issue":"19","key":"10.1016\/j.rdc.2012.08.004_bib113","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.rdc.2012.08.004_bib114","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1471-2474-9-52","article-title":"Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety","volume":"9","author":"Alonso-Ruiz","year":"2008","journal-title":"BMC Musculoskelet Disord"},{"issue":"7","key":"10.1016\/j.rdc.2012.08.004_bib115","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1136\/ard.2008.091025","article-title":"The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events","volume":"68","author":"Leombruno","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.rdc.2012.08.004_bib116","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","article-title":"Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2012.08.004_bib117","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/acr.20129","article-title":"Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register","volume":"62","author":"Dixon","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.rdc.2012.08.004_bib118","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1186\/ar2904","article-title":"Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT","volume":"12","author":"Strangfeld","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.rdc.2012.08.004_bib119","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/ard.2004.030528","article-title":"Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas","volume":"64","author":"Geborek","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2012.08.004_bib120","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/ard.2007.085852","article-title":"Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register","volume":"68","author":"Askling","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.rdc.2012.08.004_bib121","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1002\/art.24941","article-title":"Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?","volume":"60","author":"Askling","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.rdc.2012.08.004_bib122","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1136\/ard.2005.047514","article-title":"Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study","volume":"65","author":"Askling","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2012.08.004_bib123","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1136\/ard.2009.117762","article-title":"Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry","volume":"69","author":"Mariette","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2012.08.004_bib124","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pds.2046","article-title":"Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data","volume":"20","author":"Askling","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X12000634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X12000634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:11:51Z","timestamp":1760181111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X12000634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":124,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0889857X12000634"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2012.08.004","relation":{},"ISSN":["0889-857X"],"issn-type":[{"type":"print","value":"0889-857X"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Controversies","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2012.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}